-
Mashup Score: 0Real-World Data Support Enfortumab Vedotin+Pembrolizumab for Advanced Urothelial Cancer - Renal and Urology News - 14 day(s) ago
Investigators report findings from a retrospective study of patients treated at Mayo Clinic.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Nadofaragene Firadenovec for BCG-Unresponsive NMIBC Shows Real-World Benefit - Renal and Urology News - 14 day(s) ago
Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC). ASCO #GU25 #blcsm https://t.co/i7z8DDpRPA
-
-
Mashup Score: 0
“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” says Thomas Powles, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Updated data from the phase 3 EV-302 trial showed that enfortumab vedotin plus pembrolizumab continued to demonstrate superior efficacy vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. #GU25 #blcsm @tompowles1 https://t.co/7EZ5GvkIhx
-
-
Mashup Score: 0
“The efficacy findings reported to date are 71% any time response,” says John A. Taylor III, MD, MS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
John A. Taylor III, MD, MS, shares the design and preliminary findings of the phase 2 LEGEND trial, which is exploring detalimogene voraplasmid in patients with BCG-unresponsive NMIBC. #GU25 #blcsm https://t.co/m7HdGsoSQE
-
Treatment with enfortumab vedotin plus pembrolizumab improves outcomes in patients with locally advanced or metastatic urothelial carcinoma. ASCO #GU25 #blcsm https://t.co/l9H7sFkQcs